Ðǿմ«Ã½

    Advertisement
    Tucson Sentinel17:49FDA US Senate Donald Trump
    pharmaphorum06:29FDA US Senate Donald Trump
    Jezebel13:10FDA US US Politics
    Feminist Majority Foundation16:28FDA US US Politics
    Mother Jones07:39Abortion Rights
    Korea JoongAng Daily22:32Abortion pill Catholic Church
    In the last 7 days
    Jezebel13:34 2-Oct-26
    Christian Concern13:01 2-Oct-26
    WRKF10:50 1-Oct-26
    Fox News07:32 1-Oct-26
    Notes from Poland04:14 1-Oct-26
    Just The News23:49 30-Sep-26
    The Sun Daily23:10 30-Sep-26
    KY319:44 30-Sep-26
    OSV News15:44 30-Sep-26
    Jezebel15:40 30-Sep-26
    Fox News14:43 30-Sep-26
    RTL Today12:42 30-Sep-26
    France 2412:36 30-Sep-26
    Fox 812:30 30-Sep-26
    Mother Jones07:39 30-Sep-26
    Mother Jones15:47 28-Sep-26
    In the last month
    Tucson Sentinel17:49 25-Sep-26
    Jezebel13:10 25-Sep-26
    The Independent12:05 25-Sep-26
    STAT10:44 25-Sep-26
    pharmaphorum06:29 25-Sep-26
    Government Executive06:21 25-Sep-26
    Roll Call16:59 24-Sep-26
    Scientific American16:25 24-Sep-26
    Los Angeles Times15:23 24-Sep-26
    NewsMax13:44 24-Sep-26
    Times LIVE11:57 24-Sep-26
    The Washington Post08:01 24-Sep-26
    Jerusalem Post07:10 24-Sep-26
    Fox News06:49 24-Sep-26
    The Independent05:34 24-Sep-26
    ABC News05:04 24-Sep-26
    MailOnline00:11 24-Sep-26
    Hoodline18:58 23-Sep-26
    Fox News07:55 23-Sep-26
    Fox News06:54 23-Sep-26
    13abc21:39 22-Sep-26
    Local News Matters19:01 22-Sep-26
    Korea Biomedical Review00:37 22-Sep-26
    MailOnline23:30 21-Sep-26
    PBS Online18:46 21-Sep-26
    Feminist Majority Foundation16:28 21-Sep-26
    Medpage Today12:16 21-Sep-26
    CalMatters08:01 21-Sep-26
    News-Medical.Net23:33 20-Sep-26
    PR Newswire (Press Release)09:30 18-Sep-26
    Korea Biomedical Review01:04 18-Sep-26
    California Attorney General (Press Release)18:04 17-Sep-26
    The Cut09:58 17-Sep-26
    Korea JoongAng Daily05:19 17-Sep-26
    The Korea Times03:06 17-Sep-26
    Korea Biomedical Review00:55 17-Sep-26
    Korea JoongAng Daily22:32 16-Sep-26
    KFVS1217:13 16-Sep-26
    Slate15:20 16-Sep-26
    NewsMax14:20 16-Sep-26
    The Korea Times04:38 16-Sep-26
    Korea JoongAng Daily03:51 16-Sep-26
    Korea Biomedical Review01:43 16-Sep-26
    Korea JoongAng Daily01:19 16-Sep-26
    Retraction Watch21:42 15-Sep-26
    Jezebel15:33 14-Sep-26
    NTD News17:37 10-Sep-26
    KALB17:15 10-Sep-26
    KPLC05:20 10-Sep-26
    Just The News23:00 9-Sep-26
    NewsMax22:09 9-Sep-26
    Medpage Today16:32 9-Sep-26
    Courthouse News16:20 9-Sep-26
    Bloomberg Law14:21 9-Sep-26
    Law36014:17 9-Sep-26
    Talking Points Memo12:52 9-Sep-26
    NewsMax10:30 9-Sep-26
    NewsMax07:59 9-Sep-26
    Just The News07:22 9-Sep-26
    Washington Examiner06:16 9-Sep-26
    ABC News05:24 9-Sep-26
    NPR05:02 9-Sep-26
    The Washington Sun18:37 8-Sep-26
    Korea Biomedical Review03:10 8-Sep-26
    Korea JoongAng Daily21:57 7-Sep-26
    Bloomberg Law08:57 4-Sep-26
    Law36019:38 3-Sep-26
    view more headlines
    2 Oct 13:34

    About our Mifepristone news

    Latest news on Mifepristone, a medication used to terminate early pregnancies, typically those that are less than 10 weeks along. It is also known as RU-486 or the "abortion pill". Mifepristone works by blocking the hormone progesterone, which is needed for a pregnancy to continue. This causes the lining of the uterus to break down, and the pregnancy to detach and be expelled from the body.

    Mifepristone is usually taken orally, followed by a second medication called misoprostol, which is taken a few days later to help expel the pregnancy. Mifepristone is considered safe and effective when used under the guidance of a healthcare provider, and is typically used as an alternative to surgical abortion. It may also be used in certain medical conditions, such as Cushing's syndrome, where it helps to reduce the production of cortisol hormone.

    Mifepristone has been in the news recently because of a legal dispute over its approval by the US Food and Drug Administration (FDA). A federal judge in Texas ruled that the FDA had violated the law by approving mifepristone without considering its potential impacts on adolescent girls. The judge ordered the FDA to suspend its approval of the drug and conduct a new review within 30 days. The US Department of Justice has appealed against this ruling, arguing that it would endanger women's health and access to abortion. However, on the same day, a federal judge in Washington state issued a contradictory order that prevented the FDA from changing its current regulation of mifepristone, which allows the drug to be prescribed by any provider and dispensed by mail during the Covid-19 pandemic. The judge ruled that the FDA's regulation is based on scientific evidence and protects women's health and rights. The case could end up in the Supreme Court, which has a conservative majority.

    Meanwhile, some states led by Democratic governors have been stockpiling doses of mifepristone and misoprostol, the other drug used for medical abortion, to ensure their availability in case of a ban. They have also been defending their rights to provide abortion pills to their residents against pressure from Republican attorneys general in other states. The states that are suing to expand access to mifepristone are California, Colorado, Connecticut, Hawaii, Illinois, Maine, Maryland, Nevada, New Mexico, Oregon, Vermont and Washington. They argue that the restrictions on mifepristone are not supported by evidence and impose unnecessary burdens on women and health care providers.


    Publication filters

    Headline Density

    Sorry, no headlines or news topics were found. Please try different keywords.